Salivary Oxytocin as a Biomarker of Psychedelic Treatment
NCT ID: NCT07345858
Last Updated: 2026-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
80 participants
OBSERVATIONAL
2026-01-05
2026-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exploratory Study on the Mood and Cytokine Levels in Female Healthy Participants and Major Depressive Disorder Patients
NCT01533285
Model-based Defining of Subtypes of Depression and Optimal Treatment: an Integrated Techniques Module.
NCT04518592
Endogenous Opioid Mechanisms for Rejection Sensitivity
NCT02189785
Cytokine-Associated Depression and Social Pain
NCT00949845
PROSPECTIVE EVALUATION OF BLOOD BIOMARKERS AS AN AID TO DIAGNOSTIC AND TREATMENT IN DRUG-NAIVE PATIENTS WITH DEPRESSION
NCT06369792
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* MDD defined by DSM-V criteria, and resistant to treatment
* Ongoing classical psychotherapeutic treatment
* Agreement to discontinue necessary psychotropic medications (some classes of anti-depressants are allowed with no need to taper off).
Exclusion Criteria
* High suicidal risk
* Severe cardiovascular, hepatic or neurological (affecting the central nervous system) disorders
* Pregnancy or breastfeeding.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Geneva, Switzerland
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tatiana Aboulafia Brakha
PhD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Geneva University Hospitals
Geneva, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BASEC ID 2025-02092
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.